Clinical Trial Update: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of novel anti-cancer agents in patients with metastatic triple-negative breast cancer; results have been posted on 2026-02-02.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Triple Negative Breast Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-02-02